Amrutanjan Health Care Résultats passés
Passé contrôle des critères 4/6
Amrutanjan Health Care a connu une croissance annuelle moyenne de ses bénéfices de 2.4%, tandis que le secteur Pharmaceuticals a vu ses bénéfices augmenter de en hausse à 13.4% par an. Les revenus ont augmenté de en hausse à un taux moyen de 9.2% par an. Le rendement des capitaux propres de Amrutanjan Health Care est 16% et ses marges nettes sont de 10.9%.
Informations clés
2.4%
Taux de croissance des bénéfices
2.5%
Taux de croissance du BPA
| Pharmaceuticals Croissance de l'industrie | 17.5% |
| Taux de croissance des recettes | 9.2% |
| Rendement des fonds propres | 16.0% |
| Marge nette | 10.9% |
| Dernière mise à jour des bénéfices | 30 Sep 2024 |
Mises à jour récentes des performances passées
Recent updates
Amrutanjan Health Care (NSE:AMRUTANJAN) Is Paying Out A Dividend Of ₹1.00
Nov 19
Amrutanjan Health Care's (NSE:AMRUTANJAN) Dividend Will Be ₹2.60
Aug 31Amrutanjan Health Care's (NSE:AMRUTANJAN) Dividend Will Be ₹2.60
Aug 17We Think You Should Be Aware Of Some Concerning Factors In Amrutanjan Health Care's (NSE:AMRUTANJAN) Earnings
May 31Pinning Down Amrutanjan Health Care Limited's (NSE:AMRUTANJAN) P/E Is Difficult Right Now
May 03Amrutanjan Health Care (NSE:AMRUTANJAN) Has Affirmed Its Dividend Of ₹1.00
Feb 12Amrutanjan Health Care (NSE:AMRUTANJAN) Has Announced A Dividend Of ₹2.60
Sep 02Amrutanjan Health Care's (NSE:AMRUTANJAN) Dividend Will Be ₹2.60
Aug 19Amrutanjan Health Care (NSE:AMRUTANJAN) Is Due To Pay A Dividend Of ₹2.60
Aug 05Amrutanjan Health Care (NSE:AMRUTANJAN) Has Announced A Dividend Of ₹1.00
Feb 17Amrutanjan Health Care (NSE:AMRUTANJAN) Will Pay A Dividend Of ₹1.00
Nov 08Amrutanjan Health Care (NSE:AMRUTANJAN) Will Pay A Dividend Of ₹2.60
Aug 18Amrutanjan Health Care Limited (NSE:AMRUTANJAN) Vies For A Place In Your Dividend Portfolio: Here's Why
Apr 30Should You Be Adding Amrutanjan Health Care (NSE:AMRUTANJAN) To Your Watchlist Today?
Apr 08Introducing Amrutanjan Health Care (NSE:AMRUTANJAN), The Stock That Zoomed 162% In The Last Five Years
Mar 11Trade Alert: The Non-Executive Independent Director Of Amrutanjan Health Care Limited (NSE:AMRUTANJAN), Govindan Raghavan, Has Just Spent ₹72k Buying A Few More Shares
Feb 24Is It Smart To Buy Amrutanjan Health Care Limited (NSE:AMRUTANJAN) Before It Goes Ex-Dividend?
Feb 14Is Amrutanjan Health Care Limited's (NSE:AMRUTANJAN) Latest Stock Performance A Reflection Of Its Financial Health?
Feb 12Is Amrutanjan Health Care Limited (NSE:AMRUTANJAN) A Smart Choice For Dividend Investors?
Jan 30
Is There More To The Story Than Amrutanjan Health Care's (NSE:AMRUTANJAN) Earnings Growth?
Jan 17Here's Why I Think Amrutanjan Health Care (NSE:AMRUTANJAN) Is An Interesting Stock
Jan 04What Type Of Shareholders Make Up Amrutanjan Health Care Limited's (NSE:AMRUTANJAN) Share Registry?
Dec 22How Much is Amrutanjan Health Care's (NSE:AMRUTANJAN) CEO Getting Paid?
Dec 09If You Had Bought Amrutanjan Health Care (NSE:AMRUTANJAN) Stock Five Years Ago, You Could Pocket A 106% Gain Today
Nov 26Here's What We Like About Amrutanjan Health Care's (NSE:AMRUTANJAN) Upcoming Dividend
Nov 14Why Amrutanjan Health Care Limited (NSE:AMRUTANJAN) Should Be In Your Dividend Portfolio
Oct 28Are Strong Financial Prospects The Force That Is Driving The Momentum In Amrutanjan Health Care Limited's NSE:AMRUTANJAN) Stock?
Oct 10I Ran A Stock Scan For Earnings Growth And Amrutanjan Health Care (NSE:AMRUTANJAN) Passed With Ease
Sep 22What Percentage Of Amrutanjan Health Care Limited (NSE:AMRUTANJAN) Shares Do Insiders Own?
Sep 01With Amrutanjan Health Care Limited (NSE:AMRUTANJAN) It Looks Like You'll Get What You Pay For
Aug 11Have Insiders Been Selling Amrutanjan Health Care Limited (NSE:AMRUTANJAN) Shares?
Jul 29Ventilation des recettes et des dépenses
Comment Amrutanjan Health Care gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Sep 24 | 4,378 | 475 | 537 | 0 |
| 30 Jun 24 | 4,271 | 426 | 1,048 | 0 |
| 31 Mar 24 | 4,214 | 450 | 484 | 0 |
| 31 Dec 23 | 3,946 | 440 | 398 | 0 |
| 30 Sep 23 | 3,753 | 373 | 461 | 0 |
| 30 Jun 23 | 3,865 | 432 | 973 | 0 |
| 31 Mar 23 | 3,798 | 398 | 493 | 0 |
| 31 Dec 22 | 3,860 | 418 | 500 | 0 |
| 30 Sep 22 | 3,990 | 517 | 494 | 0 |
| 30 Jun 22 | 3,986 | 588 | 1,037 | 0 |
| 31 Mar 22 | 4,059 | 672 | 505 | 0 |
| 31 Dec 21 | 3,935 | 627 | 1,211 | 0 |
| 30 Sep 21 | 3,829 | 631 | 1,159 | 0 |
| 30 Jun 21 | 3,644 | 668 | 966 | 0 |
| 31 Mar 21 | 3,330 | 612 | 497 | 0 |
| 31 Dec 20 | 2,984 | 589 | 763 | 0 |
| 30 Sep 20 | 2,811 | 474 | 777 | 0 |
| 30 Jun 20 | 2,635 | 322 | 809 | 0 |
| 31 Mar 20 | 2,617 | 251 | 834 | 0 |
| 31 Dec 19 | 2,876 | 314 | 833 | 0 |
| 30 Sep 19 | 2,751 | 274 | 804 | 0 |
| 30 Jun 19 | 2,621 | 257 | 750 | 0 |
| 31 Mar 19 | 2,535 | 250 | 756 | 0 |
| 31 Dec 18 | 2,406 | 158 | 785 | 0 |
| 30 Sep 18 | 2,335 | 168 | 762 | 0 |
| 30 Jun 18 | 2,288 | 201 | 710 | 0 |
| 31 Mar 18 | 2,203 | 200 | 671 | 0 |
| 31 Dec 17 | 2,247 | 165 | 722 | 0 |
| 31 Mar 17 | 2,240 | 211 | 710 | 0 |
| 31 Mar 16 | 1,867 | 206 | 505 | 0 |
| 31 Mar 15 | 1,666 | 149 | 468 | 0 |
| 31 Mar 14 | 1,417 | 124 | 508 | 1 |
Des revenus de qualité: AMRUTANJAN a un niveau élevé de bénéfices non monétaires.
Augmentation de la marge bénéficiaire: Les marges bénéficiaires nettes actuelles de AMRUTANJAN sont plus élevées que l'année dernière AMRUTANJAN. (10.9%) sont plus élevées que l'année dernière (9.9%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: Les bénéfices de AMRUTANJAN ont augmenté de 2.4% par an au cours des 5 dernières années.
Accélération de la croissance: La croissance des bénéfices de AMRUTANJAN au cours de l'année écoulée ( 27.5% ) dépasse sa moyenne sur 5 ans ( 2.4% par an).
Bénéfices par rapport au secteur d'activité: La croissance des bénéfices AMRUTANJAN au cours de l'année écoulée ( 27.5% ) a dépassé celle du secteur Pharmaceuticals 20%.
Rendement des fonds propres
ROE élevé: Le retour sur capitaux propres de AMRUTANJAN ( 16% ) est considéré comme faible.